ID   HT-3
AC   CVCL_1293
SY   HT3
DR   CLO; CLO_0004286
DR   EFO; EFO_0002204
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-32
DR   BioSample; SAMN03472916
DR   cancercelllines; CVCL_1293
DR   Cell_Model_Passport; SIDM00679
DR   ChEMBL-Cells; CHEMBL3308745
DR   ChEMBL-Targets; CHEMBL1075470
DR   Cosmic; 760222
DR   Cosmic; 809227
DR   Cosmic; 846183
DR   Cosmic; 907068
DR   Cosmic; 925353
DR   Cosmic; 928908
DR   Cosmic; 1131521
DR   Cosmic; 1193036
DR   Cosmic; 1201774
DR   Cosmic; 1995449
DR   Cosmic; 2301540
DR   Cosmic; 2660191
DR   Cosmic; 2816219
DR   Cosmic-CLP; 907068
DR   DepMap; ACH-001525
DR   EGA; EGAS00001000978
DR   GDSC; 907068
DR   GEO; GSM253299
DR   GEO; GSM675735
DR   GEO; GSM685442
DR   GEO; GSM1669914
DR   IARC_TP53; 325
DR   IGRhCellID; HT3
DR   LINCS_LDP; LCL-1304
DR   PharmacoDB; HT3_631_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1293
DR   PubChem_Cell_line; CVCL_1293
DR   Wikidata; Q54896535
RX   DOI=10.1007/978-1-4757-1647-4_5;
RX   PubMed=77569;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=924690;
RX   PubMed=1648218;
RX   PubMed=2990217;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=7459858;
RX   PubMed=10392903;
RX   PubMed=15531914;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=24134916;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=29156801;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/ht-3-human-cervical-cell-line
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 784-01.
CC   Population: Caucasian.
CC   Doubling time: 2.48 days (PubMed=29156801).
CC   HLA typing: A*03,28; B*8,05/w35; C*w02,w03 (PubMed=77569).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Unspecified (PubMed=1648218).
CC   Transformant: NCBI_TaxID; 10611; Human papillomavirus type 30 (HPV30).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.04%; Native American=0%; East Asian, North=3.34%; East Asian, South=0%; South Asian=1.53%; European, North=55.35%; European, South=37.73% (PubMed=30894373).
CC   Caution: Indicated as originating from a 58 year old female patient in ATCC and from a 53 year old in Sloan Kettering tech transfer site.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; Cosmic-CLP; DepMap; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D18S51: 15
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 21
ST   D3S1358: 15
ST   D5S818: 10,13
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   Penta D: 12
ST   Penta E: 11,12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C9039; Cervical carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   DOI=10.1007/978-1-4757-1647-4_5;
RA   Fogh J., Trempe G.L.;
RT   "New human tumor cell lines.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=924690; DOI=10.1002/ijc.2910200505;
RA   Kerbel R.S., Pross H.F., Leibovitz A.;
RT   "Analysis of established human carcinoma cell lines for
RT   lymphoreticular-associated membrane receptors.";
RL   Int. J. Cancer 20:673-679(1977).
//
RX   PubMed=1648218; DOI=10.1073/pnas.88.13.5523;
RA   Scheffner M., Munger K., Byrne J.C., Howley P.M.;
RT   "The state of the p53 and retinoblastoma genes in human cervical
RT   carcinoma cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5523-5527(1991).
//
RX   PubMed=2990217;
RA   Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.;
RT   "Presence and expression of human papillomavirus sequences in human
RT   cervical carcinoma cell lines.";
RL   Am. J. Pathol. 119:361-366(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=10392903;
RA   Naeger L.K., Goodwin E.C., Hwang E.-S., DeFilippis R.A., Zhang H.,
RA   DiMaio D.;
RT   "Bovine papillomavirus E2 protein activates a complex
RT   growth-inhibitory program in p53-negative HT-3 cervical carcinoma
RT   cells that includes repression of cyclin A and cdc25A phosphatase
RT   genes and accumulation of hypophosphorylated retinoblastoma protein.";
RL   Cell Growth Differ. 10:413-422(1999).
//
RX   PubMed=15531914; DOI=10.1038/sj.onc.1208235;
RA   Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S.,
RA   Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H.,
RA   Schwarte-Waldhoff I.;
RT   "Smad4 deficiency in cervical carcinoma cells.";
RL   Oncogene 24:810-819(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24134916; DOI=10.1186/1755-8166-6-44;
RA   McCormack A., Fan J.-L., Duesberg M., Bloomfield M., Fiala C.,
RA   Duesberg P.H.;
RT   "Individual karyotypes at the origins of cervical carcinomas.";
RL   Mol. Cytogenet. 6:44.1-44.23(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//